Premium
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non‐Hodgkin B‐cell lymphomas
Author(s) -
Sancho JuanManuel,
Navarro Belén,
Soler Campos Joan Alfons,
Oteyza Jaime Pérez,
Barrenetxea Lekue Cristina,
Bregni Marco,
Grasso Cicala Silvina,
Spione Mario,
Mombiedro Cristina,
Soler Begoña,
Zinzani Pier Luigi
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13392
Subject(s) - medicine , refractory (planetary science) , cardiotoxicity , gastroenterology , adverse effect , lymphoma , regimen , sinus tachycardia , population , oncology , surgery , chemotherapy , physics , environmental health , astrobiology
Background and objective Few treatment options exist for patients with relapsed/refractory (R/R) B‐cell non‐Hodgkin lymphoma (NHL) who fail first‐ and second‐line therapies. Pixantrone is a novel aza‐anthracenedione agent with reduced potential for cardiotoxicity but maintained anti‐tumour activity relative to anthracyclines. The current retrospective, observational, real‐life study was undertaken in 79 patients who received pixantrone monotherapy for multiply R/R aggressive B‐cell NHL in Spain and Italy. Results Before pixantrone, patients had received a median of 3 prior therapies and 84.6% of them were refractory to the last regimen. Median progression‐free survival (mPFS) was 2.8 months (95% confidence interval [CI] 2.1‐3.6) and median overall survival (mOS) was 4.0 months (95%CI 5.6‐7.9), with an objective response rate (ORR) of 29% (complete remission [CR]: 13.2%, partial remission [PR]: 15.2%). Patients receiving ≥2 cycles of pixantrone showed mPFS and mOS of 3.1 and 6.0 months, respectively, and an ORR of 36.8% (CR: 17.5%, PR: 19.3%). Overall, 63.3% of patients reported ≥1 adverse event (AE), most commonly haematological AEs. One patient developed grade 2 sinus tachycardia. Conclusion Pixantrone was effective and well tolerated in a real‐world population of multiply R/R patients with aggressive B‐cell NHL, many of whom had very poor prognostic factors.